mProX™ Human CD274 Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;RBE;HuCCT1

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Cancer Research

Related Diseases

Composite Lymphoma; Pleural Mesothelioma

Gene ID

Human:29126

UniProt ID

Human:Q9NZQ7

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD274, also known as PD-L1, has various applications in cancer research and treatment. In gastric cancer, CD274 is part of a prognostic model that predicts patient outcomes and survival. High expression of CD274 is associated with a less favorable outcome in gastric cancer patients. CD274 is also linked to immune checkpoints and immune cells, suggesting its potential role in immunotherapeutic strategies. In metastatic urothelial carcinoma, CD274 promoter hypomethylation is a predictive biomarker for response to immune checkpoint blockade therapy. PD-L1 positivity, determined by CD274 expression, is associated with longer progression-free survival and overall survival in certain subtypes of non-small cell lung cancer (NSCLC) with EGFR mutations. CD274-induced senescence in breast cancer cells has enhanced anti-tumor immunogenic properties compared to DNA-damaging agents. Additionally, CD274 expression is used to assess the efficacy and safety of pembrolizumab, an immunotherapy, in the first-line treatment of metastatic lung cancer. Real-world data confirms the efficacy and safety of pembrolizumab in lung cancer treatment. Overall, CD274 plays a crucial role in tumor immune microenvironment analysis, immunotherapy response prediction, and treatment outcomes in various cancers.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CD274 Stable Cell Line (S01YF-1023-PY166). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Skyler Garcia (Verified Customer)

What is the significance of PD-L1 (CD274) expression in cancer prognosis? Jul 07 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

Increased PD-L1 expression in cancers like cervical squamous cell carcinoma is associated with higher TNM stage, reduced TILs, and worse prognosis, indicating its role as a prognostic marker. Jul 07 2021

chat Morgan Brown (Verified Customer)

How does the MAPK pathway influence PD-L1 expression in lung adenocarcinoma? May 21 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

The MAPK pathway activity is key in inducing PD-L1 expression in lung adenocarcinoma, suggesting a target to improve the efficacy of immunotherapy. May 21 2022

Published Data

Fig.1 Knockdown of CD274 in ICC cell lines.

A Western blot analysis was conducted to investigate alterations in FDX1 and CD274 protein levels following the transfection of siCD274 and the addition of Elescomol-Cu in RBE and Hucct1 cell lines.

Ref: Shen, Zefeng, et al. "Exploration of a screening model for intrahepatic cholangiocarcinoma patients prone to cuproptosis and mechanisms of the susceptibility of CD274-knockdown intrahepatic cholangiocarcinoma cells to cuproptosis." Cancer Gene Therapy (2023): 1-16.

Pubmed: 37828105

DOI: 10.1038/s41417-023-00673-4

Research Highlights

Klümper, Niklas. et al. "PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma." Oncoimmunology, 2023.
The relationship between PD-L1 status and outcomes on immune checkpoint blockade (ICB) in patients with metastatic urothelial carcinoma (mUC) has been evaluated using immunohistochemistry (IHC). However, the results have shown that PD-L1 status assessed by IHC is not a reliable predictor of outcomes for these patients.
Klümper, Niklas. et al. "PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma." Oncoimmunology, 2023.
Pubmed: 37868689 DOI: 10.1080/2162402X.2023.2267744

Gloriane C Luna, Herdee. et al. "The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors" Translational lung cancer research, 2023.
The tumor immune microenvironment plays a crucial role in shaping the development of non-small cell lung cancer (NSCLC). However, there is still a lack of consensus on the prognostic significance of programmed death-ligand 1 (PD-L1) in NSCLC with epidermal growth factor receptor (EGFR) mutations. Furthermore, no studies have been conducted to examine the prognostic value of PD-L1 in Filipinos with EGFR-mutant NSCLC. This topic has yet to be explored in the Filipino population.
Gloriane C Luna, Herdee. et al. "The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors" Translational lung cancer research, 2023.
Pubmed: 37854154 DOI: 10.21037/tlcr-23-118